The global nuclear medicine/radiopharmaceuticals market is expected to reach US$ 4.0 billion by 2020, registering a CAGR of 9.0% during the forecast period. Advancement in radiotracers and alpha radio immunotherapy-based targeted cancer treatment is primarily driving the nuclear medicine/radiopharmaceuticals market. In addition, the increasing use of SPECT and PET scans to detect diseases like cancer and the growing occurrence of cancer and cardiac ailments are driving the market. However, conventional diagnostic procedures are still followed in most hospitals due to cost and availability issues associated with nuclear medicine/radiopharmaceuticals, which is expected to hamper the growth of the market. In addition, the short lifespan of nuclear medicine/radiopharmaceuticals and stringent regulatory guidelines are expected to restrain the growth of the market.
We provide customization of the report to early buyers, as per requirement.
In this report, the global nuclear medicine/radiopharmaceuticals market is segmented by type, application, procedural volume, and region. Each of these segments contains diagnostic and therapeutic types. Based on type, the market is segmented into diagnostic and therapeutic nuclear medicine/radiopharmaceuticals. The diagnostic segment accounts for the largest share of the global market by type. In the diagnostic segment, the SPECT segment accounts for the largest share of the market whereas, in the therapeutic segment, the beta emitters segment holds the largest market share.
A glimpse of the report structure is provided in the report description available on the website.
Based on application, the market is segmented into diagnostic and therapeutic applications. The diagnostic application contains SPECT (cardiology, thyroid, neurology, and others) and PET (oncology, cardiology, and neurology). Nuclear medicine is used in different therapeutic applications such as bone metastasis, thyroid, lymphoma, and endocrine tumors.
The global nuclear medicine/radiopharmaceuticals market is also segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is estimated to be the largest nuclear medicine/radiopharmaceuticals market. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, and Brazil. The report includes a detailed study of global and regional nuclear medicine/radiopharmaceuticals market and analyzes the variations in the growth of the industry in certain regions.
Cardinal Health, Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt Plc (Ireland) are the most active players in the nuclear medicine/radiopharmaceuticals market.
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org